Sponsor: Lung Cancer Mutation Consortium
Sponsor Study ID: LCMC4
Study Title: Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancer
CTO #: 103745
NCT Number: NCT04712877
Phase: N/A
Protocol Type: Screening
Age Group: Adults
Disease Sites: Lung
Study Objectives: The primary objective of this study is to determine the proportion of patients with stage IA2-III lung cancers who possess actionable oncogenic drivers. The screening approach will be considered feasible if, utilizing tumor or plasma assays, 35% of non-squamous non-small cell lung cancers are identified as having a actionable genomic alteration including ALK rearrangements, BRAFV600E mutations, EGFR sensitizing mutations, HER2 mutation, HER2 amplification, MET amplification, MET exon 14 mutation, RET rearrangements, NTRK rearrangement, KRAS G12C, or ROS1 rearrangements